ChristyLynnOsgoodMD

PubMed

• 26 citations
  US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Ca...
  Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist
  Journal of Clinical Oncology. 2023-04-10
• 58 citations
  FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
  Preeti Narayan, Christy L. Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks
  Clinical Cancer Research. 2021-01-01
• 23 citations
  FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
  Jennifer J Gao, Christy L. Osgood, Yutao Gong, Hui Zhang, Erik Bloomquist
  Clinical Cancer Research. 2021-04-15

Journal Articles

• Clostridium difficile infection in the pediatric transplant patient  
  Nicholson MR, Osgood CL, Acra SA, Edwards KM, Pediatric Transplantation, 1/1/2015

Abstracts/Posters

• Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor
  Osgood CL, Maloney KN, Kidd CG, Gebregiorgis M, Woldemichale G, Nunez LE, Morís F, Helman LJ, Grohar PJ, AACR Annual Meeting, 1/1/2015
• Development of an imaging based pharmacodynamic marker of EWS/FLI1 activity for Ewing sarcoma
  Osgood CL, Buck JR, Kwangho K, Sulikowski G, Manning HC, Grohar PJ, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/1/2014
• Development of pharmacodynamic marker of EWS-FLI1 transcription factor blockade in Ewing sarcoma
  Osgood CL, Rose KL, Schey KL, Grohar PJ, Department of Pediatric Annual Research Retreat, Nashville, TN, 1/1/2013
• Emergency physicians miss treatable symptoms in active cancer
  Kennedy CL, Lucey ML, Quest TE, Acad Emerg Med, 1/1/2007
• Achieving EVR in post-liver transplant patients with chronic hepatitis C: is it a fair goal of therapy?
  Kennedy CL, McClure M, Brackett T, Fernandes B, Steinberg T, Kugelmas ME, AM J Transplant, 1/1/2004
• Heme-Onc emergencies
  Osgood CL, Pediatric Emergency Medicine Fellow’s Conference, Vanderbilt University Medical Center, 1/17/2014
• Developmental therapeutics
  Osgood CL, Vanderbilt University Medical Center Hematology/Oncology Fellows Didactic Conference Series, Nashville, TN, 1/28/2014
• Randomized controlled trial of interval compressed therapy in Ewing sarcoma
  Osgood CL, Vanderbilt University Medical Center Pediatric Oncology Didactic Conference, Nashville, TN, 1/21/2013
• VIP secreting ganglioneuroblastoma
  Osgood CL, Pediatrics Residency Chief’s Case Presentation, Vanderbilt University Medical Center, Nashville, TN, 1/13/2013
• Anemia and cancer
  Osgood CL, 3rd year Medical Student Didactic Conference, Meharry Medical College, Nashville, TN, 1/16/2013
• Myeloproliferative disorders
  Osgood CL, Pediatric Oncology Didactic Conference, Vanderbilt University Medical Center, Nashville, TN, 1/1./2012
• Hyperglycemia in induction therapy for acute lymphocytic lymphoma
  Osgood CL, Pediatric Oncology Didactic Conference, Vanderbilt University Medical Center, Nashville, TN, 1/2./2012
• Hemolytic anemia
  Osgood CL, Pediatrics Residency Chief’s Case, Vanderbilt University Medical Center, Nashville, TN, 1/2./2012
• Lymphadenopathy
  Osgood CL, Pediatrics Residency Educational Conference, Vanderbilt University Medical Center, Nashville, TN, 1/10/2010
• Chronic osteomyelitis
  Osgood CL, Pediatrics Residency Educational Conference, Vanderbilt University Medical Center, Nashville, TN, 1/21/2010
• Emergency physicians miss treatable symptoms in advanced cancer
  Osgood CL, Medical Student Research Day, Emory University School of Medicine, Atlanta, GA, 1/24/2006
• Identification of mithramycin analogs with improved targeting of the EWS-FLI1 transcription factor
  Osgood CL, Vanderbilt University Medical Center, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/22/2015
• Development of an imaging based pharmacodynamic marker of EWS-FLI1 activity for Ewing sarcoma
  Osgood CL, Vanderbilt University Medical Center, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/17/2014
• Development of a pharmacodynamic marker of EWS-FLI1 transcription factor blockade in Ewing sarcoma
  Osgood CL, Department of Pediatrics Annual Research Retreat, Nashville, TN, 1/27/2013
• Identification of mithramycin analogs with improved targeting of the EWS/FLI1 transcription factor
  Osgood CL, American Association for Cancer Research Annual Meeting, 1/20/2015
• Emergency physicians miss treatable symptoms in advanced cancer
  Osgood CL, Society for Academic Emergency Medicine Annual Meeting, Chicago, IL, 1/18/2007
• Hepatitis C treatment goals in post liver transplant patients
  Osgood CL, American Transplant Congress, Boston, MA, 1/4./2004
• Preliminary results for quantitative liver function tests for patients in the HALT-C trial
  Osgood CL, American Association for the Study of Liver Diseases, Boston, MA, 1/24/2004
• Join now to see all

Lectures

• FDA analysis of depth of response (DpR) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019